Literature DB >> 29075173

Case Report: Biliary Pancreatitis With Acute Cholangitis in a Patient Under Anticoagulant Treatment With Dabigatran.

Franziska Baumann-Durchschein1, Thomas Gary2, R B Raggam2.   

Abstract

We report a case of acute onset of a biliary pancreatitis with cholangitis presented in our emergency department. The patient was under anticoagulant therapy with dabigatran due to persistent atrial fibrillation. Pancreatic enzymes including lipase were elevated above the linear measuring range and bilirubin together with cholestasis enzymes was also highly elevated. An ERCP with papillotomy was urgently indicated because postponing could lead to further deterioration of the patient's condition. Coagulation testing showed a prolonged thrombin time above 160sec which was followed by a diluted thrombin time (Haemoclot Test) resulted in a peak-level of dabigatran thus confirming full anticoagulation. Therefore, idarucizumab (Praxbind®) was administered pre-procedural of ERCP, the patient underwent uneventful ERCP without any bleeding complications, a full recovery was achieved and the patient was scheduled for elective cholecystectomy.

Entities:  

Keywords:  anticoagulant therapy; biliary pancreatitis; bleeding; cholangitis

Year:  2017        PMID: 29075173      PMCID: PMC5655639     

Source DB:  PubMed          Journal:  EJIFCC        ISSN: 1650-3414


  6 in total

1.  Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.

Authors:  Andrew M Veitch; Geoffroy Vanbiervliet; Anthony H Gershlick; Christian Boustiere; Trevor P Baglin; Lesley-Ann Smith; Franco Radaelli; Evelyn Knight; Ian M Gralnek; Cesare Hassan; Jean-Marc Dumonceau
Journal:  Endoscopy       Date:  2017-01-23       Impact factor: 10.093

Review 2.  Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.

Authors:  Ramyashree Tummala; Ana Kavtaradze; Anjan Gupta; Raktim Kumar Ghosh
Journal:  Int J Cardiol       Date:  2016-03-28       Impact factor: 4.164

3.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

Review 4.  When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.

Authors:  J H Levy; W Ageno; N C Chan; M Crowther; P Verhamme; J I Weitz
Journal:  J Thromb Haemost       Date:  2016-02-17       Impact factor: 5.824

5.  Dabigatran: patient management in specific clinical settings.

Authors:  Paul Alexander Kyrle; Konrad Binder; Sabine Eichinger; Reinhold Függer; Bernd Gollackner; J Michael Hiesmayr; Kurt Huber; Wielfried Lang; Peter Perger; Peter Quehenberger; Franz X Roithinger; Sabine Schmaldienst; Ansgar Weltermann; Hans Domanovits
Journal:  Wien Klin Wochenschr       Date:  2014-08-20       Impact factor: 1.704

6.  Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.

Authors:  Hein Heidbuchel; Peter Verhamme; Marco Alings; Matthias Antz; Hans-Christoph Diener; Werner Hacke; Jonas Oldgren; Peter Sinnaeve; A John Camm; Paulus Kirchhof
Journal:  Eur Heart J       Date:  2017-07-14       Impact factor: 29.983

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.